Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04141644
Title Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC (Osi+Ipi)
Acronym Osi+Ipi
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors University of Utah
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Huntsman Cancer Institute Salt Lake City Utah 84112 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field